Skip to main content

Table 3 Table 3

From: Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry

Biologic medication Current use Prior use
  N (% of biologic users) N (% of biologic users)
TNF-alpha inhibitirs   
Adalimumab 78 (7) 70 (6)
Cartolizumab 4 (<1) 0
Etanercept 214 (20) 183 (17)
Gollimumab 5 (<1) 4 (<1)
Inflximab 46 (4) 46 (4)
IL-1 Inhibitors   
Ankira 14 (1) 22 (2)
Rilonacept 2 (<1) 2 (<1)
Other biologic agents   
Abatacept 24 (2) 8 (<1)
Rituximab 2 (<1) 8 (<1)
Tocilizumab 6 (<1) 0 (<1)